e-learning
resources
London 2016
Sunday, 04.09.2016
Pulmonary drug delivery
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Mesh nebulizer capabilities in aerosolizing a wide range of novel pharmaceutical formulations
Ross Hatley (Chichester, United Kingdom), Ross Hatley, Lucy Hardaker
Source:
International Congress 2016 – Pulmonary drug delivery
Session:
Pulmonary drug delivery
Session type:
Thematic Poster
Number:
967
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Ross Hatley (Chichester, United Kingdom), Ross Hatley, Lucy Hardaker. Mesh nebulizer capabilities in aerosolizing a wide range of novel pharmaceutical formulations. Eur Respir J 2016; 48: Suppl. 60, 967
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Risk factors associated with the development of interstitial lung abnormalities
Surfactant protein expression at various COPD Gold stages
Dexamethasone inhibits secretory and cytosolic phospholipases A2 in alveolar macrophages in acute lung injury
Related content which might interest you:
Development of in-vitro models for aerosolized surfactant therapy to support customization of a novel nebulizer system based on eflow technology
Source: Annual Congress 2009 - Respiratory disorders of the newborn
Year: 2009
Extent of inhaled drug deposition in mouth-throat and pulmonary airways: A novel biophysical modelling approach for inhaled therapeutics
Source: International Congress 2015 – New models for treating airway diseases
Year: 2015
Characterisation of exhaled aerosol from vibrating mesh and jet nebulisers
Source: International Congress 2016 – Occupational and environmental exposures and biomarkers: human studies, animal data, and in vitro methods
Year: 2016
Development of a novel nano-sized carrier system for aeroseol drug delivery (EGE University translational pulmonology research group)
Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD
Year: 2015
The mesh nebuliser: a recent technical innovation for aerosol delivery
Source: ISSN=ISSN 1810-6838, ISBN=, page=252
Year: 2006
Novel jet nebulizer/holding chamber for drug delivery to the deep lung
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016
Measures of nebulizer performance – Comparing like with like
Source: Annual Congress 2013 –Novel pharmacological findings in the management of respiratory disorders
Year: 2013
A novel approach of using pharmaceutical pictogram for improving asthma inhaler techniques
Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies
Year: 2018
Assessment of two different methods of bronchodilators delivery during noninvasive ventilation. Experimental in vivo approach
Source: Eur Respir J 2004; 24: Suppl. 48, 315s
Year: 2004
Watching the lung work: An in vitro 3-D microfluidic device to challenge pulmonary drug delivery strategies with high end microscopy
Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases
Year: 2013
The performance of a new vibrating mesh prototype nebulizer for inhaled biodrugs
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014
Comparative in vitro performance of the new drug aclidinium in a novel multidose dry powder inhaler
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
Novel paradigm for inhaled therapies: simulation of drug pharmacokinetic behaviour and effect of disease
Source: Eur Respir J 2003; 22: Suppl. 45, 474s
Year: 2003
Systemic exposure and lung bioavailability across two different dose strengths of CHF5993 a novel Triple pMDI
Source: International Congress 2016 – Pulmonary drug delivery
Year: 2016
Delivery of a suspension corticosteroid formulation by small volume nebulizers: a comparative bench study
Source: Eur Respir J 2001; 18: Suppl. 33, 134s
Year: 2001
Workshop 1: Lung Clearance Index – demonstration of devices utilised by the core facility; best practices and different approaches to communication with pharmaceutical companies
Source: International Congress 2016 – PD5 Establishing core facilities for measuring clinical trial outcomes
Year: 2016
Eliminating in-vitro drug-drug interactions in dual and triple fixed-dose combination therapies using a novel cosuspension metered dose inhaler platform
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013
Drug loaded liposomes of mesalamine incorporated into disease responsive microgels (Micro) for treating allergic asthma: An approach using smart drug delivery system
Source: International Congress 2015 – Is asthma always an easy disease to diagnose and manage?
Year: 2015
Efficacy and safety of a new pleural device for the ambulatory management of pneumothorax
Source: International Congress 2015 – Interventional pulmonology for pleural diseases
Year: 2015
First in class, respiratory drug gas & drug vapor delivered in a revolutionary and new portable device
Source: International Congress 2015 – Immune mechanisms in the human lung
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept